Tipifarnib Shows Early Promise as an Adjuvant in Enzalutamide-Resistant Prostate Cancer

Tipifarnib is an interesting repurposing candidate in advanced prostate cancer because it may interfere with a resistance mechanism that goes beyond androgen signaling alone. In a preclinical work presented during the AUA 2026 meeting, the drug reduced exosome release from aggressive castration-resistant prostate cancer cells, including 22Rv1 and CWR-R1, by about 30% at low dose, without an obvious loss of viability. That matters because exosomes help cancer cells share pro-survival signals and adapt to therapy pressure.

The main implication is that tipifarnib may work as an adjunct to enzalutamide rather than as a replacement for it. Enzalutamide resistance remains a major problem in castration-resistant disease, and earlier studies have already linked that resistance to increased exosome secretion and altered vesicle trafficking. Tipifarnib fits into that biology by suppressing exosome biogenesis and release, which could weaken the signaling network that supports resistant cells.

This is still early-stage evidence, so it should be read as a promising mechanistic signal, not a clinical breakthrough. There is no patient-level proof yet that tipifarnib improves outcomes in enzalutamide-resistant prostate cancer. But because tipifarnib is already a clinically known drug, the repurposing angle is especially attractive if future studies confirm the effect in vivo and in combination therapy.

Source.